Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tapentadol + oxycodone is a combination of two opioid analgesics used for pain management, particularly in cases where pain is severe and not adequately controlled by other treatments. Tapentadol acts as both a μ-opioid receptor agonist and a norepinephrine reuptake inhibitor, providing dual mechanisms for analgesia—opioid-mediated nociceptive pain relief and noradrenergic modulation of neuropathic pain. Oxycodone is a classical opioid that functions primarily as a μ-opioid receptor agonist, inhibiting ascending pain pathways in the central nervous system to alter the perception and response to pain. The combination may be considered in complex or refractory cases of severe chronic or cancer-related pain, especially when monotherapy with either agent does not provide sufficient relief[4]. Both drugs carry risks typical of opioids, including dependence, tolerance, constipation, nausea, somnolence, and potential for abuse.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tapentadol + oxycodone.